Pfenex Inc. learned late Friday that it was regaining rights to PF582, its biosimilar candidate to Lucentis (ranibizumab, Genentech Inc./Roche AG), according to Paul Wagner, the company's chief financial officer. The decision resulted from a re-prioritization of biosimilar assets by Pfizer Inc. following its acquisition of Pfenex partner, Hospira Inc.